Inclusion criteria

          -  Subject with histologically proven, locally advanced, unresectable and/or metastatic
             solid tumor, for which no standard treatment is available or the subject is refractory
             to or intolerant of existing standard treatment.

          -  Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer
             cells or DNA. Historical, local laboratory result (up to 5 years prior to this study)
             can be used for Phase 1 subjects. Phase 2 subjects must be tested for KRasG12C
             mutation by a central laboratory.

          -  Subject has tumor type requirement as follows: advanced or metastatic solid tumors
             including NSCLC and CRC.

          -  Subject has measurable disease according to RECIST, v1.1.

        Exclusion Criteria:

          -  Subject with unstable or progressive central nervous system (CNS) metastases.

          -  Subject with acute myocardial infarction, severe/unstable angina; or with cardiac
             insufficiency of New York Heart Association Functional Classification Grade 2 or
             above.

          -  Subject has corrected QT interval using Fridericia's formula (QTcF) prolongation at
             rest, where the mean QTc interval is > 480 msec based on triplicate measurements of
             electrocardiogram (ECG).

          -  Subject with stroke or other severe cerebrovascular diseases within 12 months before
             enrollment;

          -  Subject with interstitial lung disease or acute lung infection not yet recovered
             including but not limited to severe acute respiratory syndrome coronavirus 2
             (SARS-CoV-2) infection;

          -  Subject has any history or evidence of substance abuse or medical, psychological or
             social conditions that may, in the opinion of the investigator, interfere with
             participation in the study or evaluation of the study results.

          -  Subject has impaired gastrointestinal (GI) function or GI diseases that may
             significantly alter the absorption or metabolism of oral medications.

          -  Subject has unresolved toxicities from prior anticancer therapy, defined as toxicities
             (other than alopecia) not yet resolved to NCI CTCAE, v5.0, Grade ≤ 1 (Grade ≤ 2 for
             peripheral neuropathy).

          -  Subject had major surgery within 4 weeks prior to study intervention administration or
             last dose of palliative radiation therapy within 2 weeks prior to study intervention
             administration.

          -  Subject is pregnant or lactating.